BioSpace News Archive

Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the publication of preclinical study results demonstrating the superior long-term in vitro myeloma-killing activity of allogeneic anti-BCMA CAR T cells from healthy donors compared with anti-BCMA CAR T cells from patients with multiple myeloma.

Exero Medical has enrolled the first patient in its multi-center safety and feasibility study of the company’s flagship product, the xBar tissue monitoring and diagnostic system.

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), announced that it has received MHRA and Research Ethics Committee approvals to initiate gamma-delta T cell therapy clinical trials of OmnImmune® for the treatment of Acute Myeloid Leukemia (AML).

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), today announced positive two-year follow-up data for the Company’s StemSpine® pilot study, showing significant efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

BIOLASE, Inc., the global leader in dental lasers, announced that President and CEO, John Beaver, has been invited to participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the fourth quarter ended December 31, 2021 and provide a corporate strategic update on Monday, March 28, 2022.

Nova Mentis Life Science Corp. is proud to announce that it has begun the patient enrollment process for its North American Observational study: Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder and Fragile X Syndrome.

Kinetic River Corp., a leader in advanced flow cytometry technologies, announced today it has been awarded a Phase II Small Business Innovation Research (SBIR) grant funded by the U.S. National Institutes of Health (NIH).

CNS Pharmaceuticals, Inc. announced that John Climaco, CEO of CNS Pharmaceuticals will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022.